Specialized in the development of medical devices used in radiotherapy for the treatment of cancer, the company Accuray, which has 1,000 employees, owes its notoriety to two state-of-the-art equipment, the result of a doctor for the first and a physicist for the second: the CyberKnife® robot and the Radixact® system, the latest generation of the TomoTherapy® platform, allow movements to be synchronized and improve the precision of the administered dose.
AI, a practical tool at the service of adaptation
“With innovation in its DNA thanks to creative entrepreneurs, Accuray has pioneered the use of images to guide radiotherapy treatment”, explains Philippe Degreze. Personalizing the patient’s treatment involves adapting to the change in the patient’s biology. “You have to consider the patient differently every day, the tumor may have moved, their weight may have changed”. This consideration requires the ability to calculate parameters very quickly. “Adaptive becomes the Holy Grail of all radiotherapy.”
In this logic of real-time adaptation, AI is consolidated as a valuable tool at the service of efficiency and revolutionizes radiotherapy treatments. “AI allows us to process information in real time that the human brain could not or would take too long to do”
Quality control procedures
While “the rays” are sometimes subject to demonization, they are still controlled by one or more human operators, whether dosimetrists, radiation therapy technicians, physicists, or doctors. In this way, AI saves time and remains under human control. Additionally, like everything in radiation therapy, AI adoption is codified through written quality documentation protocols.
“ If AI is a practical reality, the fact is that the act of caring is still a human act.”. In a world where tasks are increasingly specialized and repetitive, the machine is capable of monitoring the patient’s movement without distraction, “The goal remains to provide comfort to the patient during treatment.”
This content was produced in partnership with OpenMedias. The BFM Business editorial team was not involved in the production of this content.
Source: BFM TV
